Abstract
Objectives: The incidence rates of acute pancreatitis (AP) and the prevalence of class III obesity, and metabolic syndrome (MetS) are increasing in the US. Since class III obesity was associated with adverse clinical outcomes of AP, we sought to understand if the presence of metabolic comorbidities collectively recognized, as MetS were associated with worse clinical outcomes and increased health-care utilization. Methods: The Nationwide Readmissions Database (NRD) (2010–2014) was reviewed to identify all adult subjects with a principal discharge diagnosis of AP. Inpatient mortality, severe AP (SAP), and 30-day readmissions were the primary outcomes analyzed. Propensity score weighted analyses were used to compare AP subjects with and without MetS and were further stratified by class III obesity status. Results: MetS was associated with 12.91% (139,165/1,078,183) of all admissions with AP. Propensity score weighted analyses showed that MetS was associated with an increased proportion of SAP (OR 1.21, 95% CI 1.17, 1.25), but decreased mortality (OR 0.62, 95% CI 0.54, 0.70) and 30-day readmissions (OR 0.86, 95% CI 0.83, 0.89). Propensity score weighted analyses also revealed that class III obesity was independently associated with increased mortality in AP subjects with (OR 1.92, 95% CI 1.41, 2.61) and without MetS (OR 1.55, 95% CI 1.26, 1.92), and increased SAP in subjects with and without MetS. Conclusions: Class III obesity appears to be the primary factor associated with adverse clinical outcomes in subjects with MetS admitted with AP. This has significant implications for patient management and future research targeting AP.
Original language | English |
---|---|
Pages (from-to) | 1287-1295 |
Number of pages | 9 |
Journal | Pancreatology |
Volume | 20 |
Issue number | 7 |
DOIs | |
State | Published - Oct 2020 |
Bibliographical note
Publisher Copyright:© 2020
Funding
Research reported in this publication was supported by The National Cancer Institute (NCI) R01CA223204 (ZC-M) and U01DK108327 by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Cancer Institute (NCI) (DC, ZC-M, and PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this publication was supported by The National Cancer Institute (NCI) R01CA223204 (ZC-M) and U01DK108327 by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Cancer Institute (NCI) (DC, ZC-M, and PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | |
National Childhood Cancer Registry – National Cancer Institute | U01DK108327, R01CA223204 |
National Institute of Diabetes and Digestive and Kidney Diseases |
Keywords
- Acute pancreatitis
- Body mass index
- Class III obesity
- Metabolic syndrome
- Nationwide readmissions database
- Obesity
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Gastroenterology